HC Wainwright Increases TG Therapeutics (NASDAQ:TGTX) Price Target to $55.00

TG Therapeutics (NASDAQ:TGTX - Get Free Report) had its target price upped by analysts at HC Wainwright from $49.00 to $55.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a "buy" rating on the biopharmaceutical company's stock. HC Wainwright's price objective would indicate a potential upside of 112.68% from the stock's current price.

Several other brokerages have also issued reports on TGTX. TD Cowen assumed coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They issued a "buy" rating and a $50.00 target price for the company. The Goldman Sachs Group increased their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a research report on Tuesday. Finally, B. Riley boosted their target price on TG Therapeutics from $29.00 to $34.00 and gave the stock a "buy" rating in a research report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $37.67.

TG Therapeutics Price Performance

NASDAQ TGTX traded up $1.50 during trading on Tuesday, reaching $25.86. The company's stock had a trading volume of 3,955,272 shares, compared to its average volume of 3,648,657. The firm has a fifty day moving average of $23.51 and a 200 day moving average of $20.17. TG Therapeutics has a one year low of $9.81 and a one year high of $26.99. The stock has a market capitalization of $4.00 billion, a PE ratio of -258.00 and a beta of 2.19. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The company had revenue of $83.90 million during the quarter, compared to analysts' expectations of $81.68 million. During the same period in the prior year, the business earned $0.73 earnings per share. The company's revenue for the quarter was down 49.4% compared to the same quarter last year. Analysts expect that TG Therapeutics will post 0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On TG Therapeutics

Several institutional investors have recently bought and sold shares of the stock. NBC Securities Inc. grew its holdings in TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 485 shares during the last quarter. Blue Trust Inc. boosted its holdings in shares of TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock worth $35,000 after purchasing an additional 849 shares during the period. Ashton Thomas Private Wealth LLC bought a new stake in shares of TG Therapeutics in the second quarter worth about $35,000. ORG Wealth Partners LLC purchased a new position in TG Therapeutics during the 3rd quarter valued at about $53,000. Finally, Values First Advisors Inc. bought a new position in TG Therapeutics during the 3rd quarter valued at approximately $58,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.